Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Abstract Background To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of...

Descripció completa

Dades bibliogràfiques
Autors principals:	Maximilian Günther, Leopold Hentschel, Markus Schuler, Theresa Müller, Katharina Schütte, Yon-Dschun Ko, Ingo Schmidt-Wolf, Ulrich Jaehde
Format:	Article
Idioma:	English
Publicat:	BMC 2023-07-01
Col·lecció:	BMC Cancer
Matèries:	Patient-reported outcomes PRO-CTCAE Breast cancer Symptom burden Multiple myeloma Prostate cancer
Accés en línia:	https://doi.org/10.1186/s12885-023-11115-7

Ítems similars

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
per: Mille Guldager Christiansen, et al.
Publicat: (2023-07-01)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
per: Minji K. Lee, et al.
Publicat: (2020-12-01)

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
per: Christina Baeksted, et al.
Publicat: (2017-09-01)

Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
per: Evalien Veldhuijzen, et al.
Publicat: (2020-10-01)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives
per: Minasian LM, et al.
Publicat: (2022-12-01)

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
per: Kristin M. Schroeder, et al.
Publicat: (2023-06-01)

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer
per: Thomas Jordan, et al.
Publicat: (2024-04-01)

Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients
per: Minji K. Lee, et al.
Publicat: (2021-09-01)

Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
per: Caterina Caminiti, et al.
Publicat: (2024-10-01)

Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial
per: Lisa M. Wintner, et al.
Publicat: (2020-10-01)

Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: A single-center registry experience
per: Brady S. Laughlin, et al.
Publicat: (2022-08-01)

Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials
per: Nilesh Ranjan, et al.
Publicat: (2022-05-01)

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
per: Yanyan Zhu, et al.
Publicat: (2023-03-01)

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
per: Stacy Davis, et al.
Publicat: (2023-12-01)

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients
per: Marieke van Son, M.D., et al.
Publicat: (2021-03-01)

Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary
per: Faith A.P. Zeng, et al.
Publicat: (2022-12-01)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
per: Agnese Barnabei, et al.
Publicat: (2022-03-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
per: Shah, V, et al.
Publicat: (2020)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
per: Roman O. Kowalchuk, et al.
Publicat: (2021-11-01)

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
per: Marwan A. Alrasheed, et al.
Publicat: (2024-06-01)

Myeloma and Cystoisospora belli
per: Pathum Sookaromdee, et al.
Publicat: (2021-08-01)

A Case Report of Multiple Myeloma Concurrent with Gastric Adenocarcinoma
per: Marziyeh Ghalamkari, et al.
Publicat: (2022-07-01)

Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient [version 1; referees: 2 approved]
per: Arber Kodra, et al.
Publicat: (2015-10-01)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]
per: Albane Joly-Battaglini, et al.
Publicat: (2016-01-01)

Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity
per: Imke Ortland, et al.
Publicat: (2022-08-01)

Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents
per: Yuko Shirouchi, et al.
Publicat: (2024-08-01)

Clinical profile of patients with cardiac amyloidosis in India
per: Bishav Mohan, et al.
Publicat: (2023-01-01)

Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy
per: Seungwoo Cha, et al.
Publicat: (2018-12-01)

Gallbladder Metastases: A Report of Two Cases
per: Mohamad Mouchli, et al.
Publicat: (2019-03-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
per: Diego Acosta-Alvear, et al.
Publicat: (2015-09-01)

CYTOKINE REGULATION IN THE COURSE OF MULTIPLE MYELOMA PROGRESSION
per: O. V. Smirnova, et al.
Publicat: (2015-06-01)

Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial
per: Michael J. Hassett, et al.
Publicat: (2022-06-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
per: Aiken Dao, et al.
Publicat: (2022-12-01)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
per: Camila Bragança Xavier, et al.
Publicat: (2022-05-01)

Using a multi-omics approach to identify novel targets in multiple myeloma
per: James-Bott, A
Publicat: (2022)

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer
per: Daniel Vargas P. de Almeida, et al.
Publicat: (2023-11-01)

Palliative care outpatients in a German comprehensive cancer center—identifying indicators for early and late referral
per: S. Müller, et al.
Publicat: (2022-12-01)

A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways
per: Parinya Samart, et al.
Publicat: (2022-07-01)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
per: Schmidt-Wolf, Ingo G. H., et al.
Publicat: (2011-01-01)

Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors
per: Xiang Zhou, et al.
Publicat: (2024-04-01)